Funding Opportunity RFA-HL-19-029 from the NIH Guide for Grants and Contracts. This FOA invites clinical studies to elucidate sleep and circadian mechanisms that contribute to the risk of opiate use disorder (OUD), the pathobiology of opiate withdrawal, and that influence the response to medication-assisted treatment (MAT). Studies are needed to apply advances in understanding sleep and circadian biology to improving our understanding of OUD, the directionality of sleep and OUD interactions, and the opportunities to improve therapy and outcome. Multi-disciplinary, multiple-investigator teams combining expertise in clinical research, mechanisms of sleep and circadian rhythms, neurobiology of OUD, and neuropharmacology of MAT are strongly encouraged. This FOA is only open to the study of OUD relevant mechanisms and pathobiology. Evaluating the efficacy of one or more interventions without a rigorous mechanistic study design should not be proposed.

Funding Opportunity RFA-AT-19-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to conduct efficient, large-scale pragmatic trial or implementation science study designs to improve pain management and reduce the use of opioid medications. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to an implementation phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative is to identify effective methods to improve the management of pain and reduce the need for opioid medications at the health care system level. This FOA requires that the intervention under study be embedded into health care delivery system, real world settings. Studies can propose to integrate interventions that have demonstrated efficacy into health care system; or implement health care system changes to improve adherence to evidence-based guidelines. Trials must be conducted across two or more health care systems (HCS) and must be conducted as part of the NIH HCS Research Collaboratory supported through the NIH Common Fund. (See https://commonfund.nih.gov/hcscollaboratory). The NIH HCS Research Collaboratory Program has established a Collaboratory Coordinating Center (CCC) that is providing national leadership and technical expertise in all aspects of research with HCS. After awards are made by NIH, the CCC (http://rethinkingclinicaltrials.org/about-nih-collaboratory/) and the NIH will work with successful awardees from this FOA to facilitate the planning and rapid execution of high impact trials that conduct research studies in partnerships with health care delivery systems.

Notice NOT-NS-19-014 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-003 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-19-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes on Drug Abuse (NIDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications to develop technologies to provide science- and research-based solutions to the national opioid crisis and offer new hope for individuals, families, and communities affected by this devastating crisis. United States SBCs that have the research capabilities and technological expertise to contribute to NIDA R and D mission identified in this FOA are encouraged to submit SBIR grant applications in response to the FOA topics.

Funding Opportunity RFA-DA-19-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes on Drug Abuse (NIDA), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications to develop technologies to provide science- and research-based solutions to the national opioid emergency and offer new hope for individuals, families, and communities affected by this devastating crisis. United States SBCs that have the research capabilities and technological expertise to contribute to NIDA R and D mission identified in this FOA are encouraged to submit STTR grant applications in response to the FOA topics.

Funding Opportunity RFA-AT-19-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to conduct an efficient, large-scale pragmatic trial or implementation science study to evaluate the impact of and how best to implement acupuncture treatment for chronic low back pain into health care delivery. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to an implementation phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. Trials must be conducted across two or more health care systems (HCS) and must be conducted as part of the NIH HCS Research Collaboratory supported through the NIH Common Fund. (See https://commonfund.nih.gov/hcscollaboratory). The NIH HCS Research Collaboratory Program has established a Collaboratory Coordinating Center (CCC) that is providing national leadership and technical expertise in all aspects of research with HCS. After awards are made by NIH, the CCC (http://rethinkingclinicaltrials.org/about-nih-collaboratory/) and the NIH will work with successful awardees from this FOA to facilitate the planning and rapid execution of high impact trials that conduct research studies in partnerships with health care delivery systems.

Funding Opportunity RFA-AT-19-007 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications to expand research activities funded under RFA-AT-18-002 and RFA-DA-18-005 on the impact of interventions designed to improve adherence to Medication Assisted Treatment (MAT) or linking individuals with Opioid Use Disorders (OUD) who receive naloxone for the reversal of overdose to MAT within the context of states use of the SAMHSA Opioid STR grant funds authorized under the 21st Century Cures Act. Expansion of research activities should increase the generalizability of findings to allow for more rapid dissemination and implementation of successful interventions. Examples of additional activities include but are not limited to adding recruitment/study sites, increasing the overall sample size, targeting under-represented populations, and adjusting for longer follow-up.

Funding Opportunity RFA-HD-19-025 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites applications from investigators willing to participate with the NICHD + others for an observational clinical study of infants born to mothers who are exposed to prenatal opioids. The public health opioid epidemic has a significant effect on infants who were exposed prenatally to opioids. This funding opportunity announcement (FOA) is intended to support multi-site clinical research devoted to investigating the impact of prenatal opioid exposure on infant outcomes as well as neuroimaging in opioid exposed versus unexposed newborns. The objective of this program is to advance scientific research that facilitates knowledge and care for infants exposed in utero to opioids. This program benefits the public: infants and families with opioid exposure and their health care providers. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating sites develop a specific protocol across the sites and are organized to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and each consortium includes a mechanism for coordination, implementation and monitoring of the protocol across sites, quality control, database management, statistical analysis, and reporting. Public Law 115-141, the Consolidated Appropriations Act of 2018 (signed on March 23, 2018) includes a requirement that grantees from for-profit applicant organizations must provide a 50% match and/or in-kind contribution of all federally awarded dollars under the grant award (direct costs, as well as facilities and administrative costs) for research related to opioid addiction, development of opioid alternatives, pain management and addiction treatment.

Funding Opportunity RFA-NS-19-018 from the NIH Guide for Grants and Contracts. HEAL Initiative: This is a HEAL Initiative UH3 FOA that will solicit device applications to treat pain.

Funding Opportunity RFA-NS-19-017 from the NIH Guide for Grants and Contracts. HEAL Initiative: This is a HEAL Initiative U44 FOA that will solicit applications for devices to treat pain. There will be a Fast-track and Direct to Phase 2 Option.

Funding Opportunity RFA-EB-18-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

Funding Opportunity RFA-NS-19-025 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers (hubs) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (hubs). The purpose of this funding opportunity announcement (FOA) is to invite applications for the hubs within EPPIC-Net. A hub will typically be a regional medical center that will actively enroll subjects into clinical trials and studies performed in EPPIC-Net. Each hub should have ready access to patient populations with specific pain conditions and have expertise in characterization of that pain condition. A hub will additionally provide scientific leadership and administrative oversight to its multiple (2-10) satellite sites (spokes). This FOA solicits applications EPPIC-Net Specialized Clinical Centers. Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-18-036) and Data Coordinating Center (RFA-NS-18-035). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership, as described above, or from separate NIH funding announcements.

Funding Opportunity RFA-NS-19-023 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Clinical Coordinating Center (CCC) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Partnership. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in-depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (Hubs). The CCC will both help design and facilitate the implementation of clinical trials and studies. This FOA solicits applications for EPPIC-Net CCC. Separate FOAs have been issued to solicit applications for the Data Coordinating Center (RFA-NS-18-035) and Specialized Clinical Centers (RFA-NS-18-037). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership or from separate NIH funding announcements.

Funding Opportunity RFA-NS-19-024 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Data Coordinating Center (DCC) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Partnership. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (hubs). As the main data manager for pain research in the HEAL Initiative, the EPPIC-Net DCC will host and manage clinical, neuroimaging, biomarker, omics, and preclinical data from EPPIC-Net and other components of the HEAL Initiatives pain research program. The DCC will also make these data and clinical biosamples available to the research community to advance the science of pain. Lastly,the DCC will provide leadership in the statistical design and analysis of EPPIC-Net studies, and the systems and processes for data collection, management, quality assurance and reporting. This FOA solicits applications for the EPPIC-Net Data Coordinating Center (DCC). Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-18-036) and Specialized Clinical Centers (RFA-NS-18-037). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL initiative, as described above, or from separate NIH funding announcements.

Funding Opportunity RFA-AR-19-027 from the NIH Guide for Grants and Contracts. NIH has identified a set of research priorities reflecting urgent unmet needs across the lifespan, areas of promising scientific opportunity, and concrete strategies capable of providing rapid and durable solutions to the opioid crisis including improved understanding of the biological underpinnings of chronic pain and discovery and testing of new non-addictive pain treatments.

Funding Opportunity RFA-AR-19-029 from the NIH Guide for Grants and Contracts. NIH has identified a set of research priorities reflecting urgent unmet needs across the lifespan, areas of promising scientific opportunity, and concrete strategies capable of providing rapid and durable solutions to the opioid crisis including improved

Funding Opportunity RFA-AR-19-026 from the NIH Guide for Grants and Contracts. NIAMS intends to publish a Funding Opportunity Announcement focused on acute and chronic back pain research using novel, inter and multidisciplinary integrated approaches and novel analytics for discovery of disease mechanisms and features for deep patient phenotyping and identification of new targets for intervention.

Notice NOT-OD-19-042 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-028 from the NIH Guide for Grants and Contracts